Par Health recalls two lots of Brevital Sodium 500 mg/vial over particles found in the product
The product contains particulate matter identified as cellulose, and giving it could cause life-threatening problems including pulmonary emboli, blocked blood vessels, and inflamed vein walls that may lead to clotting.
What to do
The recall is to the hospital level, so hospitals that have these two lots of Brevital Sodium 500 mg/vial CIV (Methohexital Sodium for Injection, USP) should act on the notice. The notice does not give further steps here, so read the official notice for details.
Recall details
- Product
- Par Health Issues Voluntary Nationwide Recall of Two Lots of Brevital® Sodium 500 mg/vial CIV (Methohexital Sodium for Injection, USP) Due to the Presence of Particulate Matter
- Company
- Par Health
- Hazard
- FOR IMMEDIATE RELEASE - ROCHESTER, MI– October 8, 2026 –Par Health is voluntarily recalling two lots of Brevital® Sodium 500 mg/vial CIV (Methohexital Sodium for Injection, USP) to the hospital level. The product is being recalled due to the presence of particulate matter identified as cellulose.
- Company announcement
- October 8, 2026
The headline, summary and steps above are written in plain English from the official notice below. Identifiers are copied exactly as the agency published them. Always check the official notice before you act.
Official notice
The notice's own wording from FDA.
Par Health Issues Voluntary Nationwide Recall of Two Lots of Brevital® Sodium 500 mg/vial CIV (Methohexital Sodium for Injection, USP) Due to the Presence of Particulate Matter
- Announcement
- FOR IMMEDIATE RELEASE - ROCHESTER, MI– October 8, 2026 –Par Health is voluntarily recalling two lots of Brevital® Sodium 500 mg/vial CIV (Methohexital Sodium for Injection, USP) to the hospital level. The product is being recalled due to the presence of particulate matter identified as cellulose. Administration of Brevital® Sodium 500 mg/vial CIV (Methohexital Sodium for Injection, USP), found to contain particulate matter, has a reasonable probability of causing life-threatening adverse health consequences including pulmonary emboli (blockage in pulmonary blood vessels), occlusions of other blood vessels (which can lead to tissue death and possible organ damage), and/or inflammation of the walls of veins, which may lead to clotting. To date, Par Health has not received any reports of adverse events related to this recall.
Related recalls
Par Health recalls Argatroban Injection 250 mg/2.5 mL vials over particles found in the liquid
Particles identified as cellulose, polystyrene, polyethylene terephthalate, stopper material and possibly stainless steel were found in certain lots, which could cause life-threatening blood vessel blockages or vein inflammation.
Par Health USA, LLC · 20,935 units
Par Health recalls Buprenorphine HCl injection 0.3 mg/mL vials over crystallization in the vials
The injection was found to have crystallization, which was identified as Buprenorphine free base, and 46,334 units were sent out across the USA.
Par Health USA, LLC · 46,334 units
OneSource Specialty Pharma recalls methohexital sodium injection vials over failed impurity and degradation tests
The 500 mg multiple dose vials of methohexital sodium for injection failed testing for impurities and degradation, meaning the medicine did not meet required quality standards.
Onesource Specialty Pharma Limited · 4284 vials
QuVa Pharma recalls methohexital sodium injection over failed impurity and degradation tests
The compounded drug methohexital sodium, 100 mg/10 mL, failed its impurity and degradation specifications, meaning the medicine may not meet quality standards.